Story perspectives

FDA Approves Leucovorin for Folate Deficiency, Rejects Autism Claims

3/12/2026

Summary

Story summary

On March 10, 2026, the U.S. Food and Drug Administration approved leucovorin for treating cerebral folate deficiency.
The FDA decision contradicts claims by the Trump administration that leucovorin could benefit children with autism.
FDA officials said there is insufficient evidence that leucovorin treats autism.
After the September announcement, prescriptions for leucovorin rose 71%, causing shortages and disappointing parents.
Experts urged evidence-based treatment approaches for autism.

1 of 1

Story summary

On March 10, 2026, the U.S. Food and Drug Administration approved leucovorin for treating cerebral folate deficiency.
The FDA decision contradicts claims by the Trump administration that leucovorin could benefit children with autism.
FDA officials said there is insufficient evidence that leucovorin treats autism.
After the September announcement, prescriptions for leucovorin rose 71%, causing shortages and disappointing parents.
Experts urged evidence-based treatment approaches for autism.